VM-1500 + raltegravir

VM-1500 + raltegravir** is a pharmaceutical combination under investigation for drug-drug interaction and pharmacokinetics, primarily in the context of antiretroviral therapy. VM-1500 is an investigational compound (precise class not specified in public sources). Raltegravir is a first-in-class HIV-1 integrase inhibitor, approved for treatment of HIV infection. Raltegravir blocks the action of HIV integrase, preventing viral DNA from integrating into the host genome. The combination is being explored for possible synergistic or pharmacokinetic compatibility, particularly in healthy volunteers[1][2].

Brand names

Isentress

Other names

VM-1500 + raltegravirVM1500 + raltegravir